Deucravacitinib for treating moderate to severe plaque psoriasis

Final draft guidance

Final draft guidance (PDF 215 KB)

Committee papers (PDF 6.72 MB)

Public committee slides (PDF 1.94 MB)

Final scope (MSWord 100 KB)

Final stakeholder list (MSWord 80 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (MSWord 42 KB)

Draft scope post referral (PDF 244 KB)